JP2024524552A5 - - Google Patents

Info

Publication number
JP2024524552A5
JP2024524552A5 JP2024500258A JP2024500258A JP2024524552A5 JP 2024524552 A5 JP2024524552 A5 JP 2024524552A5 JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024524552 A5 JP2024524552 A5 JP 2024524552A5
Authority
JP
Japan
Application number
JP2024500258A
Other languages
Japanese (ja)
Other versions
JP2024524552A (ja
JPWO2023281007A5 (https=
Filing date
Publication date
Priority claimed from GBGB2109894.2A external-priority patent/GB202109894D0/en
Priority claimed from GBGB2112976.2A external-priority patent/GB202112976D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/068974 external-priority patent/WO2023281007A1/en
Publication of JP2024524552A publication Critical patent/JP2024524552A/ja
Publication of JPWO2023281007A5 publication Critical patent/JPWO2023281007A5/ja
Publication of JP2024524552A5 publication Critical patent/JP2024524552A5/ja
Pending legal-status Critical Current

Links

JP2024500258A 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン Pending JP2024524552A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2109894.2 2021-07-08
GBGB2109894.2A GB202109894D0 (en) 2021-07-08 2021-07-08 Novel treatments
GB2112976.2 2021-09-10
GBGB2112976.2A GB202112976D0 (en) 2021-09-10 2021-09-10 Novel treatments
PCT/EP2022/068974 WO2023281007A1 (en) 2021-07-08 2022-07-07 Melflufen for use in the treatment of multiple myeloma

Publications (3)

Publication Number Publication Date
JP2024524552A JP2024524552A (ja) 2024-07-05
JPWO2023281007A5 JPWO2023281007A5 (https=) 2025-07-10
JP2024524552A5 true JP2024524552A5 (https=) 2025-07-10

Family

ID=82702963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500258A Pending JP2024524552A (ja) 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン

Country Status (5)

Country Link
US (1) US20240307480A1 (https=)
EP (1) EP4366721A1 (https=)
JP (1) JP2024524552A (https=)
TW (1) TW202317084A (https=)
WO (1) WO2023281007A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121349A1 (en) * 2022-12-08 2024-06-13 Oncopeptides Ab Therapeutic treatment for haematological cancer based on the level of t-cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
CA3024230C (en) 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
PL3866931T3 (pl) 2018-10-18 2023-06-19 Oncopeptides Ab Związki zawierające deuter
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Similar Documents

Publication Publication Date Title
JP2024524552A5 (https=)
CL2025002730A1 (es) Estructuras de reacción microfluídica
BR102023008688A2 (https=)
BR102023005164A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
CN307048666S (https=)
BY13158U (https=)
CN307049887S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
CN307049815S (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13167U (https=)
BY13166U (https=)
BY13165U (https=)
BY13164U (https=)
BY13162U (https=)
BY13161U (https=)
BY13145U (https=)